MX2024011338A - Moléculas bifuncionales pequeñas para dirigir la degradación selectiva de proteínas circulantes. - Google Patents

Moléculas bifuncionales pequeñas para dirigir la degradación selectiva de proteínas circulantes.

Info

Publication number
MX2024011338A
MX2024011338A MX2024011338A MX2024011338A MX2024011338A MX 2024011338 A MX2024011338 A MX 2024011338A MX 2024011338 A MX2024011338 A MX 2024011338A MX 2024011338 A MX2024011338 A MX 2024011338A MX 2024011338 A MX2024011338 A MX 2024011338A
Authority
MX
Mexico
Prior art keywords
receptor
small molecules
crbm
moiety
target
Prior art date
Application number
MX2024011338A
Other languages
English (en)
Spanish (es)
Inventor
David Spiegel
David Caianiello
Mengwen Zhang
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/695,645 external-priority patent/US12485178B2/en
Application filed by Univ Yale filed Critical Univ Yale
Publication of MX2024011338A publication Critical patent/MX2024011338A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024011338A 2022-03-15 2024-09-13 Moléculas bifuncionales pequeñas para dirigir la degradación selectiva de proteínas circulantes. MX2024011338A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/695,645 US12485178B2 (en) 2018-04-09 2022-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins
PCT/US2023/064470 WO2023178202A2 (en) 2022-03-15 2023-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins

Publications (1)

Publication Number Publication Date
MX2024011338A true MX2024011338A (es) 2024-12-06

Family

ID=88024440

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011338A MX2024011338A (es) 2022-03-15 2024-09-13 Moléculas bifuncionales pequeñas para dirigir la degradación selectiva de proteínas circulantes.

Country Status (8)

Country Link
EP (1) EP4493222A2 (https=)
JP (1) JP2025509730A (https=)
KR (1) KR20240166514A (https=)
CN (1) CN119255822A (https=)
AU (1) AU2023236291A1 (https=)
IL (1) IL315579A (https=)
MX (1) MX2024011338A (https=)
WO (1) WO2023178202A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022310356A1 (en) 2021-07-14 2024-01-25 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
WO2025219911A1 (en) * 2024-04-16 2025-10-23 Biohaven Therapeutics Ltd. Treatment of diseases with monoclonal antibody drugs and molecular degraders
WO2025248469A1 (en) * 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. TREATMENT OF IgG-RELATED DISEASES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2997444A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
US12364766B2 (en) * 2018-04-09 2025-07-22 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
WO2019199621A1 (en) * 2018-04-09 2019-10-17 Yale University Bi-functional molecules to degrade circulating proteins
CN113301925A (zh) * 2018-12-19 2021-08-24 小利兰·斯坦福大学理事会 用于溶酶体靶向的双官能分子以及相关的组合物和方法
IL294515A (en) * 2020-01-31 2022-09-01 Avilar Therapeutics Inc Compounds bind asgpr to degrade extracellular proteins

Also Published As

Publication number Publication date
JP2025509730A (ja) 2025-04-11
EP4493222A2 (en) 2025-01-22
AU2023236291A1 (en) 2024-10-03
CN119255822A (zh) 2025-01-03
WO2023178202A2 (en) 2023-09-21
IL315579A (en) 2024-11-01
WO2023178202A3 (en) 2023-10-26
KR20240166514A (ko) 2024-11-26

Similar Documents

Publication Publication Date Title
MX2024011338A (es) Moléculas bifuncionales pequeñas para dirigir la degradación selectiva de proteínas circulantes.
MX2025012651A (es) Moléculas pequeñas bifuncionales para dirigirse a la degradación selectiva de proteínas circulantes
Brandina et al. Enolase takes part in a macromolecular complex associated to mitochondria in yeast
AR080942A1 (es) Produccion de proteinas heteromultimericas
AU2013280693B2 (en) Split inteins, conjugates and uses thereof
WO2021142377A3 (en) Cell surface receptor binding compounds and conjugates
DK1654776T3 (da) Membran-elektrode-enhed til elektrokemiske anordninger
DK1846974T3 (da) Membran-elektrode samlinger til brændstofceller, deres fremstilling og anvendelse og brændstofceller indeholdende disse
WO2020142672A3 (en) Anti-tcr antibody molecules and uses thereof
EA201070602A1 (ru) Системы и способы для улавливания и фиксации газов и получаемые при этом композиции
EA201000490A1 (ru) Антигенсвязывающие белки, связывающиеся с человеческим белком gm-csf
WO2023288033A8 (en) Asgpr cell surface receptor binding compounds and conjugates
TW200735447A (en) Laminated electrolyte membrane for solid polymer fuel cells, membrane-electrode combine and fuel cells
WO2002061105A8 (en) Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
DK1166382T3 (da) Fremstilling af rørformige brændstofceller, brændstofcellemoduler, grundelementer og ionbyttermembraner
BR122019022434B8 (pt) método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular
AR048025A1 (es) Plantas con actividad aumentada de una enzima fosforilante del almidon
NO20073797L (no) Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA)
ZA202000961B (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
ATE537188T1 (de) Serumalbuminbindende proteine
Ramírez et al. Characterization of the single-subunit oligosaccharyltransferase STT3A from Trypanosoma brucei using synthetic peptides and lipid-linked oligosaccharide analogs
TW200623499A (en) Polymer electrolyte material, polymer electrolyte component, membrane electrolyte complex, and polymer electrolyte fuel cell
GB2464888A (en) Compositions and methods for detecting and modulating cell death by a translation regulated gene expression system
CY1118782T1 (el) Επιλογη κυτταρων που εκφραζουν ετερομερη πολυπεπτιδια
WO2006098484A3 (en) Graft polymer